ADAM17 overexpression is associated with poorer clinical outcomes in cancer patients: a systematic review and meta-analysis

Abstract

ADAM17 (a disintegrin and metalloproteinase 17) is overexpressed in many types of cancer, and its high expression in cancer patients is associated with increased risk of metastasis and a poorer prognosis. However, the clinical value of ADAM17 as a tumor biomarker remains largely unknown. In this meta-analysis, we investigated the relationships between ADAM17 levels, cancer metastasis, and patient prognosis. Twelve eligible studies involving a total of 1816 patients were identified in searches of the PubMed, Embase, Cochrane, and Chinese National Knowledge Infrastructure databases. Analysis of these studies revealed that ADAM17 overexpression is positively associated with lymph node metastasis in a fixed effect model and distant metastasis in a random effect model. Moreover, high ADAM17 expression was predictive of shorter overall and progression-free survivalof cancer patients in fixed effect models. These results suggest that ADAM17 maybe a useful biomarker for predicting metastasis and prognosis in cancer patients and may also aid in risk stratification and selection of individualized treatments.

Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis

“…ADAM17 expression is associated with poor survival (HR = 2.04, 95% CI = 1.66–2.52, p < 0.001), lymph node metastasis (OR = 5.47, 95% CI = 3.98–7.51, p < 0.001) and distant metastasis (OR = 3.50, 95% CI = 1.79–6.87, p < 0.001) in many types of tumors [ 177 ]. In a meta-analysis by Ni et al increased expression of ADAM17 in GC was significantly associated with poor survival, TNM stage and lymph node metastasis [ 178 ].…”